Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, Immunocompetent men and women in good health of any ethnic group~* History of recurrent episodes of genital herpes for at least 12 months~* Seropositive for Herpes Simplex Virus HSV Type 2~* Body Mass Index (BMI) between 18 and 35 kg/m2~Exclusion Criteria:~* Present episode of genital herpes~* Intake of systemic drug against HSV or any topical application against HSV within 7 days before randomization for the trial~* Intake of systemic corticosteroids, other immunomodulating agents or any investigational agent within 3 months before randomization for the trial~* Positive results in any of the virology tests for human immunodeficiency virus antibody (HIV-Ab), hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose regimen 1 (Type: EXPERIMENTAL): None
- Dose regimen 2 (Type: EXPERIMENTAL): None
- Dose regimen 3 (Type: EXPERIMENTAL): None
- Dose regimen 4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).